Director's Confidence Visible as Elanco Leader Buys 10,000 Shares
Key Points
The director upped their stake by 10,000 shares.
This purchase increased the insider's direct equity holdings by 10%.
The shares were acquired directly.
Paul Herendeen, Director at Elanco Animal Health (NYSE:ELAN), purchased 10,000 shares of common stock on Aug. 7, 2026, according to an SEC Form 4 filing.
Company snapshot
- Elanco Animal Health is a healthcare company based in Indianapolis.
- The firm creates, produces, and commercializes solutions for companion animals and livestock, including vaccinations and preventative parasiticides.
- Market capitalization: $11.8 billion.
- Trailing twelve-month revenue: $5 billion.
- Trailing twelve-month net income: -$199 million.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $236,800 |
| Shares purchased | 10,000 |
| Post-transaction shares (directly held) | 111,687 |
| Post-transaction value | $2.4 million |
Transaction value based on SEC Form 4 weighted average purchase price ($23.68); post-transaction value based on Aug. 7, 2026, market close ($22.12).
Key questions
- How does the execution price compare to recent market levels?
The transaction was completed at $23.68 per share, which sat above the $22.12 market close as of Aug. 7, 2026. - What is the scale of the insider's total ownership following this move?
After this 10% increase in direct holdings, the director owns 0.0224% of the company's common stock, equivalent to a market value of $2.47 million as of the Aug. 7, 2026, close. - What has been the recent trajectory of the stock relative to this acquisition?
Elanco shares returned 34% over the 12 months ending on the Aug. 7, 2026, transaction date. - What is the current financial profile of the company?
The company generated $5 billion in revenue over the trailing twelve months but reported a net loss of $199 million during that same period.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-07) | $22.12 |
| Market Capitalization | $11.8 billion |
| Revenue (TTM) | $5 billion |
| Net Income (TTM) | -$199 million |
Company Snapshot
- Elanco Animal Health develops, manufactures, and commercializes a comprehensive portfolio of pharmaceutical and health solutions for companion animals and livestock, including preventative treatments such as parasiticides and vaccinations under brands like Seresto, Advantage, Advantix, and Advocate, as well as therapeutic treatments for canine and feline conditions.
- The company generates revenue through the development and commercialization of animal health products across two primary segments: companion animal health solutions for household pets and livestock health solutions for agricultural producers, leveraging its manufacturing and distribution capabilities globally.
- Elanco serves veterinarians, animal health retailers, livestock producers, and pet owners across developed and emerging markets, positioning itself as a critical supplier to the animal health ecosystem with a diversified customer base spanning companion animal and agricultural segments.
Elanco Animal Health is a leading global animal health company with $5 billion in TTM revenue and a market capitalization of $11.8 billion. The company maintains a differentiated market position through its extensive portfolio of branded pharmaceutical products and preventative health solutions, serving both the companion animal and livestock sectors. Despite current net income pressures, Elanco's diversified product offerings and established brand recognition position it as a significant participant in the growing global animal health market.
What this transaction means for investors
Shares of Elanco have performed well over the last 12 months, climbing nearly 35% compared to the nearly 20% return of the S&P 500. The animal health company is fresh off reporting its results for the second quarter of 2026, which were largely positive. Its revenue of $1.3 billion was a 10% increase from the prior-year period, and it raised its 2026 revenue guidance to $5.09 billion to $5.14 billion. CEO Jeff Simmons noted on the company's earnings release that Zenrelia, a medication designed to control itching in dogs, was Elanco's largest revenue contributor. According to one global survey, allergic skin disease and itchy skin are two of the most common reasons why dog owners bring their pets to a veterinarian.
As mentioned earlier, the stock has performed well over the last 12 months, and Herendeen now owns nearly 112,000 shares. While the Elanco stock price has been relatively flat thus far in 2026, this purchase could be seen as a sign of confidence in the company's future. According to Grand View Research, the global pet health market is expected to grow in value from $75.3 billion in 2026 to $156 billion by 2033.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.